This announcement contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)

(Stock Code: 6622)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board and the Directors of our Company are pleased to announce the unaudited consolidated interim results of our Group for the six months ended June 30, 2025, together with the comparative figures for the corresponding period in 2024 as follows. The interim financial report has been reviewed by the Audit Committee and our auditors, KPMG.

In this announcement, "Zhaoke Ophthalmology", "we", "us" and "our" refer to the Company or where the context otherwise requires, the Group.

FINANCIAL HIGHLIGHTS

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**15,803**	49,769
Cost of sales	**(7,336)**	(6,929)
Gross profit	**8,467**	42,840
Other income	**26,268**	44,514
Other net gain/(loss)	**20,012**	(8,843)
R&D expenses	**(113,050)**	(89,797)
General and administrative expenses	**(30,559)**	(31,303)
Selling and distribution expenses	**(23,421)**	(28,399)
Finance costs	**(4,340)**	(4,814)
Income tax	**–**	–
Loss for the period	**(116,623)**	(75,802)
Total comprehensive income for the period	**(195,373)**	(15,351)
Non-HKFRS Accounting Standards adjusted loss for the period[(1)]	**(115,274)**	(75,689)

Note:

(1) NON-HKFRS ACCOUNTING STANDARDS MEASURES

Non-HKFRS Accounting Standards adjusted loss for the period is defined as loss for the period adjusted by adding back equity-settled share-based payment expenses. The following table reconciles our non-HKFRS Accounting Standards adjusted loss for the period with our loss for the period.

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(116,623)**	(75,802)
Add:		
Equity-settled share-based payment expenses	**1,349**	113
Non-HKFRS Accounting Standards adjusted loss for the period	**(115,274)**	(75,689)

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Zhaoke Ophthalmology is a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address significant unmet medical needs.

We have made remarkable advancements in building a portfolio of cutting-edge assets with considerable potential across various major global markets. This includes our three flagship drug assets that are nearing market approval: Atropine Sulfate Eye Drops (NVK002) for controlling myopia progression in children and adolescents, CsA Ophthalmic Gel for managing moderate-to-severe dry eye disease, and Bevacizumab Intravitreal Injection (TAB014) for wAMD. Additionally, we have two promising drug candidates currently in clinical development: BRIMOCHOL™ PF for the treatment of presbyopia and ZKY001 for addressing corneal epithelial defects.

Our portfolio also includes a robust selection of generic assets designed to reach a wider patient demographic, which are now beginning to contribute to our revenue stream. Collectively, our innovative and generic offerings tackle significant diseases affecting both the front and back of the eye.

The global ophthalmic healthcare market presents substantial opportunities. While Greater China is our primary focus, we are strategically expanding into additional markets, including the U.S., Australia, New Zealand, the Middle East, South Korea, Malaysia, Thailand, and Indonesia.

We develop high-quality ophthalmic medicines that address unmet needs, while innovating how we bring them to market. We also champion awareness, early detection, and treatment of eye diseases. Zhaoke Ophthalmology is committed to reducing preventable vision loss and improving quality of life for patients around the world.

HIGHLIGHTS

- **Our Atropine Sulfate Eye Drops (NVK002), offered in concentrations of 0.01% and 0.02%, are currently undergoing regulatory review for market approval, enhancing our competitiveness as the second player to enter the market.** We received acceptance for review from the NMPA in January 2025 for the ANDA submission of the 0.01% dose. Additionally, in July 2025, we received acceptance for the NDA submission for the 0.02% dose. Both formulations are presently under review by the regulatory authority.

- **Our re-NDA submission for the self-developed CsA Ophthalmic Gel has been accepted by the regulator, and we have also received FDA approval to commence a Phase III trial in the U.S, demonstrating Zhaoke's robust regulatory execution capabilities and the drug's expanding international potential.** In May 2025, the NMPA accepted our NDA submission for the CsA Ophthalmic Gel. Additionally, in June 2025, we obtained FDA clearance for our IND application in the U.S.

- **The NMPA has accepted the Biologics License Application ("BLA") for Bevacizumab Intravitreal Injection (TAB014), marking the first BLA filing for a bevacizumab-based antibody indicated for wAMD in China.** The application is supported by the successful results of the company's Phase III clinical trial conducted in China.

- **We strategically expanded our global presence into several new markets, including Australia, New Zealand, Thailand, the Middle East, and Indonesia.** We achieved this by partnering with leading local pharmaceutical companies to commercialize our novel drugs, including BRIMOCHOL™ PF, our glaucoma franchise, CsA Ophthalmic Gel and Atropine Sulfate Eye Drops, in the domestic markets.

- **We also achieved significant milestones in the U.S., one of the most competitive and important markets in the global pharmaceutical industry.** In addition to the FDA clearance for the IND application for CsA Ophthalmic Gel, we established a strategic partnership with the leading American pharmaceutical company Somerset Therapeutics LLC in June 2025. Furthermore, we obtained Orphan Drug Designation ("**ODD**") for our proprietary formulation of melphalan aimed at treating pediatric retinoblastoma ("**RB**") in July 2025.

- **Our global standards of ophthalmic manufacturing capabilities have been further validated.** In June and July 2025, we established strategic partnerships with American pharmaceutical company, Somerset Therapeutics LLC, and French-based global contract manufacturing organization, FAREVA Group. Our state-of-the-art manufacturing facility in Nansha, Guangzhou will serve as the production base for their and their customers' ophthalmic drugs.

- **We ensured a strong financial foundation for a successful future.** As of the end of June 2025, we had cash and cash equivalents (together with time deposits that have an original maturity of more than three months) totaling approximately RMB1,054.2 million, which supports Zhaoke's research and development, as well as commercialization activities in the coming years.

BUSINESS REVIEW

Pipeline Strategy

Zhaoke Ophthalmology has established a comprehensive portfolio of innovative and generic drugs that address six major eye diseases across both the front and the back of the eye. These major ophthalmic indications are DED, myopia, presbyopia, wAMD/DME, glaucoma and CED. In some areas, we have chosen multiple drug candidates to address these diseases, as we believe this is the best way to treat their multiple and complex underlying causes.

Research & Development (R&D)

Research and development underpin all our activities. While we have successfully transformed Zhaoke Ophthalmology into a joint R&D-commercial organization, we remain dedicated to achieving clinical advancements in all our innovative and generic drugs. As such, we made solid progress in advancing our late-stage drug assets over the Reporting Period.

Innovative Drugs

Our Company has several strategically important innovative drugs which we expect to move through the pipeline during the next few years.

Atropine Sulfate Eye Drops (NVK002) for myopia (partnered with Vyluma)

Overview

To date, low concentration atropine has been widely studied and demonstrated to be effective in myopia progression control among children and adolescents. Zhaoke Ophthalmology's Atropine Sulfate Eye Drops is currently positioned as a pioneering, clinically-proven pharmaceutical product for treating the progression of myopia in China.

- This treatment has a proprietary formulation that successfully addresses the instability of low-concentration atropine. It has patent protection in both the US and China and is preservative-free with an expected shelf life of over 24 months.

- Zhaoke Ophthalmology has successfully concluded two Phase III clinical trials for Atropine Sulfate Eye Drops in China: a one-year clinical trial ("**Mini-CHAMP**"), and a two-year clinical trial ("**China CHAMP**").

- Mini-CHAMP involved 16 centers and 526 patients, and was led by Principal Investigators Professor Qu Xiao Mei, from the Eye and ENT Hospital of Fudan University, and Professor Yang Xiao, from the Zhongshan Ophthalmic Center of Sun Yat-Sen University. China CHAMP involved 18 centers and 777 patients and was led by Professor Wang Ning Li from Beijing Tongren Hospital as the Principal Investigator.

Updates during and after the Reporting Period

- Following the completion of the Mini-CHAMP Phase III clinical trial, we submitted an ANDA in 2024 based on the results from the Phase III clinical trial. In January 2025, the NMPA officially accepted the ANDA for Atropine Sulfate Eye Drops (low-dose atropine 0.01%).

- In June 2025, we passed on-site regulatory inspections for Atropine Sulfate Eye Drops 0.01%.

- In July 2025, we received acceptance for review from the NMPA for the NDA submission of Atropine Sulfate Eye Drops (0.02% dose).

- Zhaoke's Atropine Sulfate Eye Drops continues to be well-positioned as the second low-dose atropine product to market. Furthermore, Zhaoke is currently the only company in China with two specifications of Atropine Sulphate Eye Drops undergoing regulatory review.

CsA Ophthalmic Gel for DED (self-developed)

Overview

CsA Ophthalmic Gel is an innovative drug being developed by Zhaoke Ophthalmology for the treatment of moderate to severe DED.

- It is a single, daily dose hydrogel which eliminates daytime administration and the associated discomfort and inconvenience. As such, it aims to dramatically improve patients' treatment compliance and quality of life.

- The proprietary hydrogel formulation is protected by patent approval in China and internationally. This novel formulation enhances the pharmacokinetic profiles of CsA on the ocular surface, giving CsA more time to exert its effect on DED. However, unlike current treatments, CsA Ophthalmic Gel's unique formulation stays on the eye for longer and administered only once every night. Compared with twice-a-day dosing for traditional products, CsA Ophthalmic Gel is expected to significantly improve patients' compliance and quality of life.

- In our pivotal Phase III clinical trial ("**COSMO**"), which involved 41 clinical trial centers with a total of 644 patients enrolled, the treatment also showed faster onset of action by demonstrating efficacy at around the two-week time period. By contrast, other CsA drugs often take around seven to eight weeks to display onset of action.

Updates during and after the Reporting Period

- In April 2025, we recruited the first patient for an additional Phase III clinical trial of CsA Ophthalmic Gel in China. This additional trial is expected to provide us with a significant competitive advantage for out-licensing the drug in other regions around the world.

- After conducting further data mining and post-hoc analysis of the previously completed COSMO study, we had a pre-NDA discussion with the CDE and subsequently refiled the NDA submission. In May 2025, the NMPA officially accepted the submission for review.

- In June 2025, we announced that the FDA had cleared our IND application for CsA Ophthalmic Gel to initiate a Phase III clinical trial in the U.S. That upcoming study is set to be a Phase III, multicenter, randomized, double-masked, active-controlled study. Based on comprehensive scientific communication and discussions with the FDA, we aligned with the FDA to incorporate data from the previously completed COSMO study, as well as the ongoing Phase III trial in China, into the U.S. development plan.

Bevacizumab Intravitreal Injection (TAB014) for wAMD (partnered with TOT BIOPHARM)

Overview

Our Bevacizumab Intravitreal Injection is the first clinical-stage bevacizumab-based antibody indicated for wAMD in China. Bevacizumab is a clinically validated, anti-Vascular endothelial growth factor (anti-VEGF) drug. Globally, bevacizumab is approved for oncology treatment through intravenous infusion. However, there has been increasing off-label usage of bevacizumab via intravitreal injection for the treatment of wAMD.

- The Phase III clinical trial of Bevacizumab Intravitreal Injection is a randomized, double-blind, and non-inferiority study. The main objective of the study is to evaluate the change from baseline in best corrected visual acuity (BCVA) at week 52 in a Bevacizumab Intravitreal Injection -treated subject group compared with the Lucentis®-treated subject group.

- The study involves up to approximately 60 centres and a total of 488 patients and is led by Professor Chen Youxin from Peking Union Medical College Hospital as the Principal Investigator.

Updates during and after the Reporting Period

- In January 2025, we announced positive top-line results from the clinical trial. The trial successfully met its primary and key secondary endpoints. Following this, a BLA was submitted to the NMPA.

- In June 2025, the NMPA officially accepted our BLA for Bevacizumab Intravitreal Injection, marking it the first bevacizumab-based antibody filing BLA indicated for wAMD in China.

BRIMOCHOL™ PF and CARBACHOL™ PF for presbyopia (partnered with Tenpoint)

Overview

BRIMOCHOL™ PF and CARBACHOL™ PF are pupil-modulating eye drops designed to be once-daily, preservative-free therapeutics to correct the loss of near vision associated with presbyopia.

- BRIMOCHOL™ PF is a fixed-dose combination of carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). CARBACHOL™ PF is a proprietary, preservative-free formulation of carbachol monotherapy.

- Both investigational therapies reduce the size of the pupil resulting in a "pinhole effect" so that only centrally focused light rays are able to enter the eye, thereby sharpening both near and intermediate images.

- Zhaoke Ophthalmology's licensing partner for BRIMOCHOL™ PF and CARBACHOL™ PF is Tenpoint, a clinical-stage US pharmaceutical company focused on developing innovative ophthalmic therapies.

Updates during and after the Reporting Period

- In January 2025, our licensing partner Tenpoint announced their positive topline results from BRIO-II, the company's second Phase III pivotal trial. In the study, BRIMOCHOL™ PF, successfully met the pre-specified visual acuity primary endpoints for both the US and EU/UK with highly statistically significant near vision improvements over eight hours.

- In June 2025, Tenpoint announced that the U.S. FDA has accepted the NDA for BRIMOCHOL™ PF for the treatment of presbyopia.

- We have started the patient enrollment for the Phase I and II clinical trials in China. On March 24, 2025, the first patient was successfully enrolled for the Phase II clinical trial. We anticipate finishing the Phase II clinical trial by the end of 2025.

ZKY001 (self-developed)

ZKY001 is a seven-amino acid peptide derived from the functional fragment of Thymosin β4 that binds actin, a type of protein that plays a central role in cell structure and movement.

- ZKY001 has broad applications in the healing of corneal wounds and can potentially be used in multiple corneal repair indications.

- Zhaoke Ophthalmology has conducted Phase II clinical trials and an investigator-initiated trial of ZKY001 for multiple potential indications, including CED; TPRK; pterygium; and NK.

- Following analysis of the results from our multiple clinical studies, our research and clinical teams chose to focus on TPRK, and specifically the treatment of corneal epithelial defects after eye surgery, as the indication for ZKY001. Once approved for a first indication, we believe ZKY001 will quickly be adopted for other corneal repair applications. We are under discussion with the CDE for the Phase III clinical trial protocol.

Melphalan for pediatric retinoblastoma (self-developed)

Melphalan, an alkylating chemotherapeutic agent, exerts its anti-cancer effects by chemically modifying DNA strands within tumor cells. This process creates cross-links that disrupt DNA replication and transcription, selectively targeting rapidly dividing cancer cells while offering potential advantages for localized administration in pediatric retinoblastoma ("**RB**"), a rare pediatric eye cancer.

Currently, Melphalan is given as the conditioning regimen prior to autologous stem cell transplantation in patients with multiple myeloma, or as the palliative treatment of multiple myeloma if oral therapy is not appropriate.

- In July 2025, the U.S. FDA granted Orphan Drug Designation ("**ODD**") to Zhaoke's proprietary formulation of melphalan for the treatment of pediatric RB.

- Securing ODD establishes a clear regulatory pathway toward IND submission in the U.S. If Melphalan is successfully developed and approved, the Company would become eligible for seven years of U.S. market exclusivity upon NDA approval. This comprehensive protection encompasses marketing authorization holder ("**MAH**") status, data exclusivity, and crucially, prevents FDA approval of any other melphalan-based product for the RB indication during this period – regardless of formulation innovations.

- While no competing therapies are currently approved for RB indication, Zhaoke remains committed to rapid development to maintain its potential first-mover advantage.

- The company is preparing for a pre-IND discussion with the FDA.

PAN-90806 (VEGFR2 inhibitor) for wAMD and DME

PAN-90806 is an innovative drug indicated in the treatment of wAMD, as well as DME, the leading cause of blindness in diabetic patients worldwide.

PAN-90806 is a novel eye drop formulation, which decreases the number of injections required. If approved as a maintenance therapy, PAN-90806 will bring significant convenience and a less invasive treatment alternative for patients. This will reduce the frequency of intravitreal injections and other treatment issues associated with mainstream anti-VEGF therapies while at the same time maintaining visual stability. PAN-90806 is expected to significantly reduce treatment discontinuation, and therefore slow underlying disease progression through improved patient comfort, acceptance, convenience and compliance.

- We have optimized the formulation of PAN-90806 and, based on completed pharmaceutical and non-clinical studies, developed a comprehensive clinical study protocol.

- Following successful results from the pre-IND communication with NMPA in June 2025, we are now prepared to submit the IND application.

Generic drugs

We have built a balanced development pipeline spanning breakthrough therapies and high-quality generics. As eye disease awareness rises across Asia, demand for accessible generics is growing. The depth of our innovative and generic portfolios enables us to deliver comprehensive solutions for ophthalmologists and patients across the region.

As of the date of this announcement, we have obtained market approvals for all six generic drugs in our glaucoma pipeline, forming a complete glaucoma product portfolio for managing intraocular pressure. They are:

- **Bimatoprost Timolol eye drop (晶贝莹®)** – the first of our generic portfolio to reach commercialization, coming to market in February 2023. This is a drug researched, developed and manufactured by Zhaoke Ophthalmology, and it is the first generic drug of Bimatoprost Timolol eye drop for the treatment of glaucoma/ocular hypertension in China.

- **Bimatoprost eye drop (晶贝清®)** – it is a prostaglandin analog used to treat open-angle glaucoma and ocular hypertension. We received the marketing authorization from the regulator in September 2024. It is the first preservative-free, single-dose Bimatoprost eye drop commercially available in China.

- **Latanoprost eye drop** – it is a PGA monotherapy eye drop that is used to treat open-angle glaucoma and ocular hypertension. We received the marketing authorization from the regulator in December 2024.

- **Latanoprost Timolol eye drop** – it is a combination PGA and blocker eye drop to lower IOP. Latanoprost timolol eye drop is an alternative therapy for resistant open-angle glaucoma. It has a dual mechanism of action, which can help achieve target IOP for patients who do not respond sufficiently to eye drops containing only PGAs or blockers. We received the marketing authorization from the regulator in March 2025.

- **Travoprost eye drop** – it is a PGA monotherapy eye drop that is used to treat open-angle glaucoma and ocular hypertension. We received the marketing authorization from the regulator in December 2024.

- **Travoprost Timolol eye drop** – it is a combination of PGA and β-blocker eye drop to lower IOP in adult patients with open-angle glaucoma or ocular hypertension. Travoprost Timolol eye drop can be an alternative therapy for patients with open-angle glaucoma who do not achieve satisfactory intraocular pressure reduction with monotherapy. It has a dual mechanism of action, which can further lower IOP for patients who do not respond sufficiently to eye drops containing only PGAs or β-blockers. We received the marketing authorization from the regulator in December 2024 .

In addition, in August 2025, we obtained an NMPA medical device registration certificate for TONO-i, a medical device for IOP measurement. TONO-i is a portable, contactless tonometer that eliminates the need for anaesthesia and reduces contamination risks. It aims to enhance glaucoma diagnosis and treatment rates in China by allowing ophthalmologists to monitor IOP conveniently and accurately. This technology helps improve patient compliance with glaucoma treatments by providing instant feedback on their effectiveness.

This portfolio lets us serve more glaucoma patients across China and empowers physicians to choose the most appropriate medication based on each patient's specific condition

Meanwhile, we are hopeful of receiving regulatory approvals in the coming months for our epinastine eye drop targeting allergic conjunctivitis (Epinastine HCl).

WARNING UNDER RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET OUR DRUG CANDIDATES SUCCESSFULLY.

R&D Team

Zhaoke's research and development capabilities are underpinned by an international cohort of seasoned ophthalmology professionals whose expertise spans the global pharmaceutical and biotechnology sectors. As at the end of the Reporting Period, our R&D team consisted of approximately 70 specialists.

R&D Expenses

For the six months ended 30 June 2025, the Company's R&D expenses were approximately RMB113.1 million, increasing by approximately RMB23.3 million from RMB89.8 million for the same period of 2024. The increase was primarily driven by the commencement of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, along with the initiation of an additional Phase III clinical trial for CsA Ophthalmic Gel during the Reporting Period.

Our R&D expenses demonstrate the overall status of the Company's R&D programs, which have a strong focus on bringing products to market quickly and effectively.

Commercialization

Since 2024, Zhaoke has transformed into an R&D-commercial enterprise. We are proud to share that in addition to the previously approved glaucoma drugs: Bimatoprost Timolol Eye Drop (晶贝莹®), Bimatoprost eye drop (晶贝清®), Latanoprost eye drop, Travoprost eye drop, and the Travoprost Timolol eye drop; and Eyprotor, a treatment for corneal ulcers we brought in in November 2023, we have also successfully brought two more ophthalmic drugs to the market.

In February 2025, we launched China's first preservative-free Azelastine eye drop targeting allergic conjunctivitis (顺敏®), in collaboration with Seefunge Pharmaceutical Technology Co., Ltd., a Zhejiang-based ophthalmic company. In March 2025, our remaining treatment for glaucoma, Latanoprost Timolol eye drop, was approved by the regulator for market authorization. Therefore, we now have a total of eight ophthalmic drugs approved for market commercialization.

We continued to execute an omni-channel sales and marketing strategy that delivers a seamless experience across every touchpoint. Traditional channels remain a cornerstone: throughout the Reporting Period, our commercialization team placed great emphasis on expanding the distribution network for ophthalmic drugs. By the end of June 2025, we had established coverage in 1,200+ public hospitals across 30 provinces in China, with a strategic focus on top-tier institutions, including Beijing Tongren Hospital, the Eye and ENT Hospital of Fudan University, Zhongshan Ophthalmic Center, and Aier Eye Hospitals. Besides, we are also deepening our relationships with private hospitals and leading ophthalmic institutions, including optical centers.

In parallel, we expanded our digital footprint. Flagship stores on JD Health (京东健康) and Tmall (天猫) enhance accessibility and brand reach, while our content-led WeChat platform, Zhaoke Boshi (兆科博视), has become a premier forum where KOLs share insights and drive discussion – now with 15,600 followers, representing nearly half of China's ophthalmology community.

We are commencing commercialization preparations to gear up for major launches over the next year, including Atropine Sulfate Eye Drops, CsA Ophthalmic Gel, and Bevacizumab Intravitreal Injection.

To amplify these initiatives, we will continue to strengthen both traditional and digital channels – building strategic collaborations with leading eye hospitals and respected ophthalmic institutions to raise public awareness of eye health and elevate brand visibility. Our nationwide sales team will also strategically scale up to capture these opportunities and drive the next phase of growth.

Partnerships and Globalization Efforts

Growing awareness of ophthalmic diseases is extending beyond China to the wider Asia-Pacific region. Yet, access to effective treatments and medicines remains limited. To address these unmet needs, Zhaoke Ophthalmology is expanding its regional footprint while leveraging its portfolio of high-quality ophthalmic products to strengthen its brand on the global stage.

As part of this approach, Zhaoke has been actively seeking collaboration opportunities around the world to improve access to vital treatments.

- In January 2025, we entered a distribution and supply agreement with AFT Pharmaceuticals Limited, a prominent manufacturer and distributor of healthcare products in New Zealand, to commercialize BRIMOCHOL™ PF in Australia and New Zealand.

- In April 2025, we teamed up with Interpharma Public Company Limited, a leading Thai pharmaceutical enterprise, to market Atropine Sulfate Eye Drops, BRIMOCHOL™ PF, and six glaucoma medications (Bimatoprost, Bimatoprost Timolol, Latanoprost, Latanoprost Timolol, Travoprost, and Travoprost Timolol) in Thailand.

- Later in April 2025, we partnered with Lunatus Marketing & Consulting FZCO based in Dubai, a key player in the Middle East and North Africa pharmaceutical sector, for the commercialization of BRIMOCHOL™ PF across the Gulf Cooperation Council (GCC) countries.

- In June 2025, we formed a significant partnership with Jamjoom Pharmaceuticals Factory Company, a leading pharmaceutical organization in the Middle East and Africa, to market CsA Ophthalmic Gel in Saudi Arabia, the UAE, Bahrain, Kuwait, Oman, and Qatar.

- In July 2025, we joined hands with FAREVA Group, a top-tier French pharmaceutical company and contract manufacturing organization known for its expertise in household and industrial products, beauty, makeup, pharmaceuticals, and active pharmaceutical ingredients (APIs). According to the agreement, Zhaoke will be designated as the trusted partner for FAREVA's customers looking to manufacture pharmaceutical products in China.

- In August 2025, we collaborated with PT Ferron Par Pharmaceuticals, a major Indonesian pharmaceutical company, to handle the commercialization of Atropine Sulphate Eye Drops in Indonesia.

We would like to highlight our efforts in the U.S., which is one of the most important markets for us as a global pharmaceutical company. We have made significant progress and achievements that contribute to building Zhaoke's brand reputation in this market.

In June 2025, we received FDA clearance for the IND application for CsA Ophthalmic Gel, allowing us to initiate a Phase III trial in the U.S.

Additionally, in late July 2025, we obtained ODD for our proprietary formulation of melphalan, intended for the treatment of pediatric RB, a rare eye cancer in children. Securing ODD provides Zhaoke with significant strategic advantages, establishing a clear regulatory pathway toward an IND submission in the U.S. If melphalan is successfully developed and approved, we would be eligible for seven years of U.S. market exclusivity upon NDA approval.

As we explore global opportunities, we are also focused on strengthening our presence in China. In February 2025, Zhaoke and Seefunge Pharma, a rapidly growing pharmaceutical company in China, jointly announced the launch of 順敏®, the country's first single-dose azelastine hydrochloride eye drops that are free of preservatives. This product offers a more effective treatment option for patients suffering from allergic conjunctivitis.

Establishing a strong global presence is a key priority for Zhaoke, and we will continue actively seeking partnerships with leading pharmaceutical companies both in China and internationally. These alliances are essential for enhancing our visibility and reputation on the global stage.

Manufacturing

Zhaoke Ophthalmology operates a state-of-the-art manufacturing facility in Guangdong Province, China – a strategic asset with fully integrated, in-house capabilities. Equipped with advanced machinery from leading global suppliers, the facility ensures that every stage of production, dosing, filling, and packaging meets the highest international standards. This positions us to meet the stringent requirements of major global regulatory authorities, including the NMPA, FDA, and EMA.

Our ophthalmic manufacturing capabilities have gained recognition from major global players, highlighted by partnerships with Somerset Therapeutics LLC and FAREVA Group. In June 2025, we collaborated with Somerset Therapeutics to develop and produce affordable generic medicines for the U.S. market. In July 2025, we partnered with FAREVA Group, a leading French pharmaceutical company, designating Zhaoke as their trusted partner for manufacturing pharmaceutical products in China, showcasing the confidence that prominent companies place in our manufacturing capabilities.

We are currently operating four manufacturing lines at this facility, allowing us to scale our production effectively. Since obtaining NMPA marketing approval, we have been producing several products here, including Bimatoprost Timolol Eye Drop (晶贝莹®), Bimatoprost Eye Drop (晶贝清®), Latanoprost Eye Drop, Latanoprost Timolol Eye Drop, Travoprost Eye Drop, and Travoprost Timolol Eye Drop .

Additionally, we have successfully transferred the manufacturing of Atropine Sulfate Eye Drops to our state-of-the-art facility in Nansha, Guangzhou, China. Upon receiving regulatory approval, the drug will be produced at our Guangdong facility, which will significantly reduce both manufacturing time and costs. We are making comprehensive preparations for the commercial manufacturing of our Atropine Sulfate Eye Drops.

Environmental, Social and Governance (ESG) update

As a responsible corporate citizen, Zhaoke Ophthalmology is committed to fostering a sustainable healthcare sector. We continually assess the environmental and social impact of our operations and implement strategies to strengthen the sustainability of our business.

Our overarching mission, to improve global visual health, drives our dedication to social responsibility. During the Reporting Period, we organized a series of in-person and online health seminars addressing the screening, treatment, and follow-up care of conditions such as glaucoma and corneal diseases, helping to raise awareness and promote early intervention.

We are equally committed to creating a thriving workplace for our employees. Diversity, inclusion, and professional growth remain central to our culture. This year, we launched a new cycle of our highly regarded tiered mentorship program and continued our rotational scheme, offering high-performing talent the opportunity to gain hands-on experience across multiple areas of our business.

Zhaoke Ophthalmology upholds the highest standards of transparency and compliance. As part of this commitment, we publish an annual ESG (Environmental, Social, and Governance) report to share our progress and priorities with stakeholders. In April 2025, we released our fifth ESG report, outlining the strategies and initiatives that guide our socially responsible practices.

Future and Outlook

The first half of this year marks a major milestone for Zhaoke Ophthalmology since our listing on the Hong Kong Stock Exchange (HKEX). We are pleased to report significant progress in our R&D pipeline, particularly with our three core assets; Atropine Sulfate Eye Drops (0.01% and 0.02%), CsA Ophthalmic Gel, and Bevacizumab Intravitreal Injection, all of which have advanced to the NDA stage, a pivotal step toward delivering innovative treatments to patients. This achievement reflects the dedication, expertise, and unwavering commitment of our team to improving vision care.

Beyond these R&D milestones, we have expanded into several new markets, including Australia, New Zealand, the Middle East, and Indonesia, while deepening our presence in established markets such as Thailand. These strategic entries not only extend the reach of our high-quality ophthalmic portfolio but also strengthen Zhaoke's position as a global leader in eye health.

As we look toward the second half of 2025, our primary focus on the R&D side will be to maintain effective communication with regulatory bodies. Our goal is to secure market approvals for Atropine Sulfate Eye Drops, both the 0.01% and 0.02% formulations, CsA Ophthalmic Gel, and Bevacizumab Intravitreal Injection as swiftly as possible.

In addition to focusing on our core assets, we are diligently working on our other high-potential products. We are focused on completing both Phase I and II clinical trials for BRIMOCHOL™ PF; and continue progressing the development of our self-developed drug for treating corneal epithelial defects, ZKY001.

We also hopeful that we will obtain the approval of Epinastine HCl eye drop, a generic drug that targets allergic conjunctivitis, which is in the final stage of the ANDA review

Furthermore, we anticipate making progress on several assets in our early innovative pipeline, including filing the IND application to NMPA for PAN90806 targeting wAMD, as well as advancing IND discussion with the U.S. FDA for melphalan targeting pediatric RB.

As we advance our R&D pipeline, we remain focused on opportunities beyond China, adopting a global perspective to maximize the potential of our high-quality drug portfolio and position Zhaoke as a trusted, influential player in the international pharmaceutical arena.

Building on the achievements of the first half of the year, we are poised to capitalize on the decisive months ahead – a critical period preceding transformative growth. Looking ahead to 2026, we are optimistic and strongly believe that it will mark Zhaoke's most significant milestones. Anticipated market approvals for our three core drugs: Atropine Sulfate Eye Drops, CsA Ophthalmic Gel, and Bevacizumab Intravitreal Injection, will not only affirm the strength of our R&D capabilities but also open new pathways for sustained growth. Our target is to have a total of 12 commercialized drugs by the end of that year, which will significantly strengthen our revenue base and enhance our global brand presence.

This bold ambition underscores our steadfast commitment to innovation and excellence in ophthalmology. Guided by the dedication of our team and the strength of our strategic initiatives, we look forward with confidence to shaping a brighter future for Zhaoke, and for the patients whose vision and quality of life we strive to improve.

FINANCIAL REVIEW

Six months ended June 30, 2025 compared to six months ended June 30, 2024

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**15,803**	49,769
Cost of sales	**(7,336)**	(6,929)
Gross profit	**8,467**	42,840
Other income	**26,268**	44,514
Other net gain/(loss)	**20,012**	(8,843)
R&D expenses	**(113,050)**	(89,797)
General and administrative expenses	**(30,559)**	(31,303)
Selling and distribution expenses	**(23,421)**	(28,399)
Finance costs	**(4,340)**	(4,814)
Loss before taxation	**(116,623)**	(75,802)
Income tax	**–**	–
Loss for the period	**(116,623)**	(75,802)
Other comprehensive income for the period		
Item that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of financial statements of entities with functional currencies other than RMB	**(78,750)**	60,451
Total comprehensive income for the period	**(195,373)**	(15,351)
Non-HKFRS Accounting Standards Measures		
Adjusted loss for the period	**(115,274)**	(75,689)

1. Overview

For the six months ended June 30, 2025, we recorded a total loss of approximately RMB116.6 million, as compared with approximately RMB75.8 million for the six months ended June 30, 2024. This was primarily attributable to the absence of one-off license income that had been recognized in the prior period under a product license agreement. In addition, the increase in R&D expenses due to the commencement of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as the initiation of an additional Phase III clinical trial for CsA Ophthalmic Gel, had partially offset the impact of the continued reduction in administrative expenses during the Reporting Period.

2. Revenue

Our Group recorded revenue with RMB15.8 million for the six months ended June 30, 2025, as compared with RMB49.8 million for the six months ended June 30, 2024.

Excluding the one-off license income of RMB33.5 million recognized in the prior period under a product license agreement, revenue from sale of drugs and products for the six months ended June 30, 2025 amounted to RMB15.1 million, representing a slight decrease compared to RMB15.6 million for the same period in 2024.

The decrease was primarily attributable to a strategic shift in the Company's sales approach. Greater emphasis was placed on expanding the distribution network for ophthalmic drugs, accompanied by a restructuring of the sales team to focus on key sales regions. As a result, the overall sales experienced a temporary and phased reduction during the Reporting Period.

We also generated revenue of RMB0.7 million from granting the exclusive distribution rights to our worldwide business partners, including Interpharma for the commercialization of our innovative drug candidates during the Reporting Period. As at June 30, 2025, the aggregated amount of the transaction price allocated to the remaining performance obligations under our Group's existing contracts was around RMB15.1 million. The amount represents revenue expected to be recognized in the future from distribution and supply contracts entered into between the customer and our Group. We will recognize the expected revenue in future throughout the contract period.

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of HKFRS 15		
Point in time:		
Sale of ophthalmic drugs	**11,725**	13,572
Sale of other drugs	**2,622**	–
Sale of ophthalmic products	**757**	2,076
Licensing income	**–**	33,523
Over time:		
Income from exclusive distribution rights	**676**	598
Income from CMO services	**23**	–
	15,803	49,769

3. Other Income

Our Group's other income primarily consists of bank interest income and government grants, which represent one-off subsidies we have received from government authorities.

For the six months ended June 30, 2025, our Group's other income decreased to approximately RMB26.3 million, compared to approximately RMB44.5 million for the six months ended June 30, 2024. The decrease was primarily attributable to the absence of a one-off government subsidy of RMB5.1 million received in the prior period, as well as a reduction in global bank interest rates during 2025, which resulted in lower bank interest income for the Reporting Period.

4. Other Net Gain/(Loss)

For the six months ended June 30, 2025, we recorded approximately RMB20.0 million of other net gain, compared to approximately RMB8.8 million of other net loss for the six months ended June 30, 2024. Such net gain primarily consists of net foreign exchange gain incurred during the translation of EUR-denominated, USD-denominated or HKD-denominated assets and liabilities.

5. R&D Expenses

Our Group's R&D expenses primarily consisted of (i) clinical trial professional service fees, including payments to CROs, hospitals and other medical institutions, as well as testing fees incurred for preclinical studies and clinical trials; (ii) depreciation and amortization related to our R&D equipment and facilities; (iii) staff costs, including salaries, bonuses and welfare payments for R&D personnel; (iv) costs of raw materials and consumables used for R&D of our drug candidates; (v) equity-settled share-based payment for R&D personnel; and (vi) utilities.

For the six months ended June 30, 2025, our R&D expenses increased by approximately RMB23.3 million to approximately RMB113.1 million from approximately RMB89.8 million for the six months ended June 30, 2024. The increase was primarily driven by the commencement of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, along with the initiation of an additional Phase III clinical trial for CsA Ophthalmic Gel during the Reporting Period.

The following table sets forth the components of our Group's R&D expenses for the periods indicated:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Clinical trial professional service fees	**57,815**	31,156
Staff costs	**23,638**	28,922
Depreciation and amortization	**17,873**	19,587
Cost of raw materials and consumables used	**4,155**	3,008
Testing fee	**3,032**	906
Utilities	**1,798**	1,741
Others	**4,739**	4,477
Total	**113,050**	89,797

6. General and Administrative Expenses

Our general and administrative expenses primarily consist of staff costs, professional service fees for legal, consulting and auditing services, general operating expenses, depreciation in relation to our office equipment and equity-settled share-based payment for those other than R&D personnel and commercialization team.

For the six months ended June 30, 2025, our general and administrative expenses were approximately RMB30.6 million, representing a decrease of approximately RMB0.7 million from approximately RMB31.3 million for the six months ended June 30, 2024, which is primarily attributable to the decrease in employee salaries and benefits, which was partially net off by the increase of equity-settled share-based payment expenses calculated based on vesting condition over periods in the first half of 2025.

7. Selling and Distribution Expenses

Our selling and marketing expenses mainly consist of staff costs for our commercialization team and marketing & conference expenses.

Our selling and distribution expenses decreased from RMB28.4 million for the six months ended June 30, 2024 to approximately RMB23.4 million for the six months ended June 30, 2025. The reduction in selling and distribution expenses corresponded with the sales performance trend observed during the period.

8. Finance Costs

Our finance costs decreased from approximately RMB4.8 million for the six months ended June 30, 2024 to approximately RMB4.3 million for the six months ended June 30, 2025, which was primarily attributable to the adjustment of interest rate applied to bank loans under the cross-border funding arrangement.

9. Loss for the Period

As a result of the above factors, for the six months ended June 30, 2025, we recorded a loss of approximately RMB116.6 million, as compared to a loss of approximately RMB75.8 million for the six months ended June 30, 2024.

10. Non-HKFRS Accounting Standards Measure

To supplement our Group's interim consolidated financial statements, which are presented in accordance with the HKFRS Accounting Standards, we also use adjusted loss for the period as an additional financial measure, which is not required by, or presented in accordance with, the HKFRS Accounting Standards. We believe that this adjusted measure provides useful information to Shareholders and potential investors in understanding and evaluating our Group's interim consolidated results of operations in the same manner as they help our management.

Adjusted loss for the period represents the loss for the period excluding the effect of equity-settled share-based payment expenses. The term adjusted loss for the period is not defined under the HKFRS Accounting Standards. However, we believe that this non-HKFRS Accounting Standards measure is a reflection of our Group's normal operating results by eliminating the potential impact of items that the management do not

consider to be indicative of our Group's operating performance. The adjusted loss for the period, as the management of our Group believes, is adopted in the industry where our Group is operating. However, the presentation of the adjusted loss for the period is not intended to be (and should not be) considered in isolation or as a substitute for the financial information prepared and presented in accordance with the HKFRS Accounting Standards. Shareholders and potential investors of our Company should not view the non-HKFRS Accounting Standards measure (i.e. adjusted loss for the period) on a stand-alone basis or as a substitute for results under the HKFRS Accounting Standards, or as being comparable to results reported or forecasted by other companies.

The table below sets forth a reconciliation of the loss for the period to adjusted loss for the period during the periods indicated:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(116,623)**	(75,802)
Add:		
Equity-settled share-based payment expenses	**1,349**	113
Adjusted loss for the period	**(115,274)**	(75,689)

Selected Data from Interim Consolidated Statement of Financial Position

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Total current assets	**1,475,041**	1,614,912
Total non-current assets	**593,617**	628,603
Total assets	**2,068,658**	2,243,515
Total current liabilities	**(335,076)**	(313,049)
Total non-current liabilities	**(27,529)**	(30,389)
Total liabilities	**(362,605)**	(343,438)
Net current assets	**1,139,965**	1,301,863

11. Liquidity and Source of Funding and Borrowing

Our primary uses of cash are to fund our clinical trials, manufacturing, purchase of equipment and raw materials and other expenses. During the Reporting Period, we primarily funded our working capital requirements through net proceeds from the Global Offering. We closely monitor uses of cash and cash balances and strive to maintain a healthy liquidity for our operations.

As at June 30, 2025, the current assets of our Group were approximately RMB1,475.0 million, including cash and cash equivalents of approximately RMB1,051.3 million, time deposits with original maturity over 3 months of approximately RMB3.0 million, pledged bank deposits of approximately RMB343.9 million and other current assets of approximately RMB76.8 million. As at June 30, 2025, the current liabilities of our Group were approximately RMB335.1 million, including trade and other payables of approximately RMB66.8 million, amounts due to related companies of approximately RMB8.6 million, bank borrowings of approximately RMB247.6 million and other current liabilities of approximately RMB12.1 million.

Amounts due to related companies represent payable for CROs services and are unsecured, interest-free and repayable with maximum credit terms of 30 days or on demand.

As of June 30, 2025, our Group had secured bank loans of RMB247.6 million which was repayable within one year or on demand.

Our Group adopts conservative treasury policies in cash and financial management. To achieve better risk control and minimize the cost of funds, our Group's treasury is centralized. Cash is generally placed in deposits mostly denominated in USD, HKD and RMB. Our Group's liquidity and financing requirements are reviewed regularly.

12. Pledged Bank Balance

Our pledged bank balance was approximately RMB343.9 million as of June 30, 2025 (as at December 31, 2024: RMB356.3 million), representing bank balances we pledged with banks for banking facilities.

13. Key Financial Ratios

The following table sets forth the components of our key financial ratio for the dates indicated:

	As at June 30, 2025	As at December 31, 2024
Current ratio[(1)]	**4.4**	5.2
Gearing ratio[(2)]	**N/A**	N/A

Notes:

(1) Current ratio represents current assets divided by current liabilities as of the same date.

(2) Gearing ratio represents interest-bearing borrowings less cash and cash equivalents and time deposits with original maturity over three months, divided by total equity and multiplied by 100% as of the same date.

(3) As of December 31, 2024 and June 30, 2025, we were in a net cash position and thus gearing ratio is not applicable.

14. Contingent Liabilities

As at June 30, 2025, our Group did not have any significant contingent liabilities.

15. Capital Commitment

The capital commitment of our Group as at June 30, 2025 was approximately RMB89.4 million, representing a decrease of approximately RMB6.0 million as compared with that of approximately RMB95.4 million as at December 31, 2024, primarily attributable to the progress made in the construction of manufacturing facilities and R&D activities.

16. Employees and Remuneration

As at June 30, 2025, our Group had a total of 270 employees. The following table sets forth the total number of employees by function as of June 30, 2025:

Function	Number of employees	% of the total
Management	5	1.9
R&D	72	26.6
Manufacturing	59	21.9
Quality control	37	13.7
Sales and marketing	57	21.1
Environmental, health and safety	1	0.4
Administrative	39	14.4
Total	270	100.0

The remuneration of the employees of our Group comprises salaries, bonuses, employees provident fund and social security contributions, other welfare payments and equity-settled share-based payment. Our Company's emolument policy is to ensure that the remuneration offered to employees, including executive Directors and senior management, is commensurate with their skills, knowledge, responsibilities and involvement in our Company's affairs. The remuneration packages of our employees are periodically reviewed objectively and determined based on each individual's performance.

The total staff costs incurred by our Group for the six months ended June 30, 2025 was approximately RMB56.1 million, as compared to approximately RMB62.6 million for the six months ended June 30, 2024. The decrease was primarily attributable to the decrease of approximately RMB7.8 million in employee salaries and benefits in line with the decrease in headcount, which was partially net off by the increase of equity-settled share-based payment expenses of approximately RMB1.3 million.

17. Foreign Exchange Exposure

During the six months ended June 30, 2025, our Group mainly operated in Mainland China and a majority of its transactions were settled in RMB, the functional currency of our Company's primary subsidiaries. As at June 30, 2025, a significant amount of our Group's cash and cash equivalents was denominated in USD. Except for certain cash and cash equivalents, prepayments on purchases of property, plant and equipment and other payables denominated in foreign currencies, our Group did not have significant foreign currency exposure from its operations as at June 30, 2025. Our Group manages its foreign exchange risk by performing regular reviews of our net foreign exchange exposures and seeks to minimize these exposures whenever possible. We currently do not adopt any long-term contracts, currency borrowings or other means to hedge our foreign currency exposure.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2025 – unaudited

		Six months ended June 30,	
		2025	2024
	Notes	***RMB'000***	*RMB'000*
Revenue	3	**15,803**	49,769
Cost of sales		**(7,336)**	(6,929)
Gross profit		**8,467**	42,840
Other income		**26,268**	44,514
Other net gain/(loss)		**20,012**	(8,843)
R&D expenses		**(113,050)**	(89,797)
General and administrative expenses		**(30,559)**	(31,303)
Selling and distribution expenses		**(23,421)**	(28,399)
Finance costs	4(a)	**(4,340)**	(4,814)
Loss before taxation	4	**(116,623)**	(75,802)
Income tax	5	**–**	–
Loss for the period		**(116,623)**	(75,802)
Loss per share *(RMB)*	6		
Basic		**(0.21)**	(0.14)
Diluted		**(0.21)**	(0.14)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended June 30, 2025 – unaudited

		Six months ended June 30,	
		2025	2024
	Notes	***RMB'000***	*RMB'000*
Loss for the period		**(116,623)**	(75,802)
Other comprehensive income for the period			
Item that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of entities with functional currencies other than Renminbi ("**RMB**")		**(78,750)**	60,451
Total comprehensive income for the period		**(195,373)**	(15,351)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At June 30, 2025 – unaudited

	Notes	**As at June 30, 2025** ***RMB'000***	As at December 31, 2024 *RMB'000*
Non-current assets			
Property, plant and equipment		**174,354**	192,137
Intangible assets		**396,429**	413,553
Prepayments and deposits		**22,834**	22,913
		593,617	628,603
Current assets			
Inventories		**13,636**	14,901
Trade and other receivables	8	**61,945**	51,468
Investments		**–**	69,467
Amounts due from related companies		**1,297**	1,087
Pledged bank balances		**343,942**	356,295
Time deposits with original maturity over three months		**2,957**	689
Cash and cash equivalents		**1,051,264**	1,121,005
		1,475,041	1,614,912
Current liabilities			
Trade and other payables	9	**66,775**	84,688
Contract liabilities		**1,629**	1,369
Amounts due to related companies		**8,573**	4,454
Bank loans		**247,583**	212,605
Lease liabilities		**10,516**	9,933
		335,076	313,049
Net current assets		**1,139,965**	1,301,863
Total assets less current liabilities		**1,733,582**	1,930,466

	Notes	**As at June 30, 2025** ***RMB'000***	As at December 31, 2024 *RMB'000*
Non-current liabilities			
Lease liabilities		**13,298**	16,049
Contract liabilities		**13,478**	13,542
Long service payment liabilities		**127**	131
Deferred income		**626**	667
		27,529	30,389
Net assets		**1,706,053**	1,900,077
Capital and reserves			
Share capital		**–***	–*
Reserves		**1,706,053**	1,900,077
Total equity		**1,706,053**	1,900,077

* The balance represents amount less than RMB1,000.

NOTES TO THE INTERIM RESULTS ANNOUNCEMENT

(Expressed in Renminbi unless otherwise indicated)

1 BASIS OF PREPARATION

The unaudited consolidated interim financial information set out in this announcement does not constitute the Group's unaudited interim financial report for the six months ended June 30, 2025 but is extracted from that unaudited interim financial report.

The interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard ("**HKAS**") 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the consolidated financial statements for the financial year ended December 31, 2024, except for the accounting policy changes that are expected to be reflected in the consolidated financial statements for the financial year ending December 31, 2025. Details of any changes in accounting policies are set out in note 2.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA, whose unmodified review report is included in the interim financial report to be sent to shareholders. In addition, the interim financial report has been reviewed by the Company's Audit Committee.

2 CHANGES IN ACCOUNTING POLICIES

(a) New and amended standards adopted by the Group

The Group has applied the amendments to HKAS 21, *The effects of changes in foreign exchange rates – Lack of exchangeability*, issued by the HKICPA to the interim financial report for the current accounting period. The amendments do not have a material impact on the interim report as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

(b) Revenue recognition

Income from CMO services

CMO services include product development, optimization, and trial production. Income from CMO services is recognized when services are rendered.

3 REVENUE AND SEGMENT REPORTING

(a) Revenue

The principal activities of the Group are development, manufacturing and marketing of ophthalmic drugs and products.

(i) Disaggregation of revenue

Disaggregation of revenue from contracts with customers by major products or service lines is as follows:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of HKFRS 15		
Point in time:		
Sale of ophthalmic drugs	**11,725**	13,572
Sale of other drugs	**2,622**	–
Sale of ophthalmic products	**757**	2,076
Licensing income	**–**	33,523
Over time:		
Income from exclusive distribution rights	**676**	598
Income from CMO services	**23**	–
	15,803	49,769

The Group's customer base is diversified and includes one customer (six months ended June 30, 2024: one) with whom transactions have exceeded 10% of the Group's revenue. During the six months ended June 30, 2025, sale of other drugs to this customer amounted to approximately RMB2,622,000, and arose in Mainland China (six months ended June 30, 2024: licensing income from this customer amounted to approximately RMB33,523,000, and arose in Mainland China).

(ii) Revenue expected to be recognized in the future arising from contracts with customers in existence at the reporting date

As at June 30, 2025, the aggregated amount of the transaction price allocated to the remaining performance obligations under the Group's existing contracts is RMB15,107,000 (December 31, 2024: RMB14,911,000). This amount represents (i) income from granting of exclusive distribution rights of the Group's products under distribution and supply agreements; and (ii) income from CMO services agreement entered into between the Group and its customers, and will be recognized as income over the remaining contractual period.

(b) Segment reporting

Operating segments are identified on the basis of internal reports that the Group's most senior executive management reviews regularly in allocating resources to segments and in assessing their performances.

The Group's most senior executive management makes resources allocation decisions based on internal management functions and assess the Group's business performance as one integrated business instead of by separate business lines or geographical regions. Accordingly, the Group has only one operating segment and therefore, no segment information is presented.

Geographic information

The following table sets out information about the geographical location of (i) the Group's revenue from external customers and (ii) the Group's property, plant and equipment and intangible assets ("**specified non-current assets**"). The geographical location of customers is based on their operating location. The geographical location of the specified non-current assets is based on the physical location of the asset, in the case of property, plant and equipment, and the location of the operation to which they are allocated, in the case of intangible assets.

	Revenue from external customers		**Specified non-current assets**	
	Six months ended June 30,		**As at June 30,**	As at December 31,
	2025	2024	**2025**	2024
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Hong Kong (place of domicile)	**350**	457	**296,964**	313,363
Mainland China	**14,708**	48,714	**273,819**	292,327
South Korea	**601**	598	**–**	–
Others	**144**	–	**–**	–
	15,803	49,769	**570,783**	605,690

4 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging/(crediting):

(a) Finance costs

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Interest on bank loans	**3,752**	4,061
Interest on lease liabilities	**588**	753
	4,340	4,814

(b) Other items

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Amortization of intangible assets	**7,063**	6,411
Depreciation charge		
– owned property, plant and equipment	**16,286**	16,025
– right-of-use assets	**4,088**	4,056
Gain on disposal of property, plant and equipment	**–**	(559)
Fair value change of investments recognized in profit or loss		
– unrealized	**–**	(159)
– realized	**(2,352)**	–

5 INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operated.

The Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Cayman Companies Act.

There is no income tax in the Cayman Islands and accordingly, the operating results reported by the Company, is not subject to any income tax in the Cayman Islands.

No provision for Hong Kong profits tax has been provided for at the rate of 16.5% as the Group's Hong Kong entity sustained a loss for taxation purposes.

No provision for Mainland China corporate income tax has been provided for at a rate of 25% pursuant to the Corporate Income Tax Law of the PRC and the respective regulations, as the Group's PRC entities sustained a loss for taxation purposes.

6 LOSS PER SHARE

(a) Basic loss per share

The calculation of basic loss per share is based on the loss attributable to ordinary equity shareholders of the Company of RMB116,623,000 (six months ended June 30, 2024: RMB75,802,000) and the weighted average of 546,139,172 ordinary shares (six months ended June 30, 2024: 546,139,172 ordinary shares) in issue during the interim period.

(b) Diluted loss per share

Diluted loss per share is the same as basic loss per share for the six months ended June 30, 2025 and 2024, as all of the potential ordinary shares are anti-dilutive.

7 DIVIDENDS

No dividends have been paid or declared by the Company during the six months ended June 30, 2025 and 2024.

8 TRADE AND OTHER RECEIVABLES

As of the end of the reporting period, the ageing analysis of trade debtors, based on the invoice date and net of loss allowance, is as follows:

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
Within 1 month	**3,751**	857
1 to 2 months	**100**	–
2 to 3 months	**–**	78
Over 3 months but within 6 months	**220**	67
Over 6 months	**217**	377
Trade receivables, net of loss allowance	**4,288**	1,379
Value-added tax recoverable	**8,544**	7,345
Prepayments to suppliers	**53,299**	52,770
Other receivables	**18,648**	12,887
	80,491	73,002
	84,779	74,381
Represented by:		
Non-current portion	**22,834**	22,913
Current portion	**61,945**	51,468
	84,779	74,381

Trade receivables are due within 30–90 days from the date of billing.

Apart from the non-current portion disclosed above, all of the other trade and other receivables are expected to be recovered or recognized as expenses within one year.

9 TRADE AND OTHER PAYABLES

As of the end of the reporting period, the ageing analysis of trade creditors, based on the invoice date, is as follows:

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
Within 1 month	**120**	720
1 to 3 months	**–**	15
Over 3 months but within 6 months	**710**	138
Over 6 months	**–**	296
Trade payables	**830**	1,169
Payables for purchase of property, plant and equipment	**2,728**	4,634
Payroll payables	**10,952**	18,250
Accrued costs for R&D expenses	**43,321**	49,485
Payables for purchase of materials	**816**	1,612
Accrued office expenses and others	**7,163**	8,480
Other taxes payables	**965**	1,058
	65,945	83,519
Trade and other payables	**66,775**	84,688

All of the trade and other payables are expected to be settled within one year or are repayable on demand.

OTHER INFORMATION

EVENTS AFTER THE REPORTING PERIOD

There was no other significant event affecting our Group which occurred after the end of the Reporting Period up to the date of this announcement.

INTERIM DIVIDEND

The Board does not recommend the distribution of an interim dividend for the six months ended June 30, 2025.

COMPLIANCE WITH THE CG CODE

Pursuant to code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive should be separate and not be performed by the same individual. Dr. Li Xiaoyi currently serves as both the Chairman and the CEO. Dr. Li Xiaoyi has been operating and managing our Group since its establishment. Our Board believes that vesting the roles of both CEO and Chairman in the same person has the benefit of ensuring consistent leadership and efficient discharge of executive functions within our Group. We consider that the balance of power and authority of the present arrangement will not be impaired our the Board comprises seven other experienced and high-caliber individuals who would be able to offer advice from various perspectives. In addition, for major decisions of our Group, our Board will make consultations with appropriate Board committees and senior management.

Therefore, our Directors consider that the present arrangement is beneficial to and in the interest of our Company and our Shareholders as a whole and the deviation from Code provision C.2.1 of Part 2 of the CG Code is appropriate in such circumstance. Our Board will continue to review the effectiveness of the corporate governance structure of our Group in order to assess whether separation of the roles of Chairman and CEO is necessary.

In response to the amendments to the CG Code effective July 1, 2025, the Board has approved changes to the terms of reference for the nomination committee. Additionally, Mr. Wong Hin Wing, Prof. Lo Yuk Lam, and Ms. Leelalertsuphakun Wanee have been appointed as members of the nomination committee. For details, see announcements of the Company dated June 30, 2025 and July 2, 2025.

We are committed to maintain a high standard of corporate governance (which is of critical importance to our development) to protect the interest of the Shareholders. Save as disclosed in this announcement, our Directors consider that we have complied with all applicable code provisions of the CG Code as set out in Appendix C1 to the Listing Rules during the Reporting Period and up to the date of this announcement.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

We have adopted the Model Code set out in Appendix C3 to the Listing Rules as its securities code to regulate the dealing by the Directors in securities of our Company.

Having made specific enquiry of all Directors, all of them have confirmed that they have complied with the Model Code during the Reporting Period and up to the date of this announcement. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information of our Company was noted by us.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

Our Company's Shares were listed on the Stock Exchange on April 29, 2021 with a total of 123,567,500 offer Shares issued. The net proceeds from the Global Offering amounted to approximately HK$1,932.3 million, after deducting the underwriting fees, commissions and related Listing expenses. As of June 30, 2025, such net proceeds were utilized as follows:

Use of proceeds from Listing	Amount of net proceeds for planned applications *(HK$ million)*	Percentage of total net proceeds *(%)*	Utilized net proceeds as of December 31, 2024 *(HK$ million)*	Utilized net proceeds during the Reporting Period *(HK$ million)*	Unutilized net proceeds as of June 30, 2025 *(HK$ million)*	Expected time frame for unutilized amount
For the clinical development and commercialization of our two Core Products	618.34	32.00%	300.94	32.11	285.29	
1. Allocated to CsA Ophthalmic Gel	438.64	22.70%	210.54	31.61	196.49	By the end of 2026
2. Allocated to ZKY001	179.70	9.30%	90.40	0.50	88.80	By the end of 2026
The continuing R&D activities as well as commercialization of the other drug candidates in our pipeline	888.86	46.00%	681.01	56.02	151.83	
1. The continuing R&D activities of other key drug candidates	579.69	30.00%	429.37	41.20	109.12	By the end of 2026
2. The continuing R&D activities of other innovative and generic drug candidates	57.97	3.00%	57.97	–	–	–
3. The milestone payments of our other in-licensed drug candidate	96.62	5.00%	96.62	–	–	–
4. The further expansion of our sales and marketing team in anticipation of new product launches in the coming year	154.58	8.00%	97.05	14.82	42.71	By the end of 2026
Carrying out the production line expansion of our advanced Nansha manufacturing facility in anticipation of our product launches in the coming years	135.27	7.00%	135.27	–	–	–
Our business development activities and the expansion of drug pipelines	96.62	5.00%	96.62	–	–	–
Working capital and other general corporate purposes	193.23	10.00%	193.23	–	–	–
	1,932.32	100.00%	1,407.07	88.13	437.12	

As at June 30, 2025, all the unused net proceeds are held by our Company in short-term deposits with licensed banks or authorized financial institutions in Hong Kong and the PRC.

The expected timeline for utilizing the net proceeds from the Global Offering is based on the best estimation of future market conditions made by our Company and subject to changes in accordance with our actual business operation. Going forward, the net proceeds will be applied in the manner as set out in "Future Plans and Use of Proceeds" of the Prospectus. As we prioritize and reschedule our R&D plan in response to the latest market conditions and patient needs, we anticipate a slight delay in the utilization of the net proceeds allocated for the clinical development and commercialization of our two core products, compared to the originally expected time frame. Save for the foregoing, there is no change in the intended use of net proceeds as previously disclosed in the Prospectus.

PURCHASE, SALE OR REDEMPTION OF OUR COMPANY'S LISTED SECURITIES

During the Reporting Period and up to the date of this announcement, neither our Company nor any of our subsidiaries have purchased, sold or redeemed any of our Company's listed securities (including sale of treasury Shares). As of June 30, 2025, the Company did not hold any treasury Shares.

MATERIAL LITIGATION

We were not involved in any material litigation or arbitration during the six months ended June 30, 2025. Our Directors are also not aware of any material litigation or claims that were pending or threatened against our Group during the six months ended June 30, 2025.

REVIEW OF INTERIM RESULTS BY AUDIT COMMITTEE

The Audit Committee comprises one non-executive Director, namely, Ms. Tiantian Zhang, and two independent non-executive Directors, namely, Mr. Wong Hin Wing and Mr. Liew Fui Kiang. The chairman of the Audit Committee is Mr. Wong Hin Wing.

The Audit Committee has reviewed the accounting principles and practices adopted by our Group and discussed auditing, internal control and financial reporting matters, including the review of our Group's unaudited interim financial report for the six months ended June 30, 2025.

The Audit Committee reviews and assesses the effectiveness of our Company's risk management and internal control systems which cover all material financial, operational and compliance controls. The Audit Committee also reviews regularly the corporate governance structure and practices within our Company and monitors compliance fulfilment on an ongoing basis.

PUBLICATION OF THE 2025 CONSOLIDATED INTERIM RESULTS AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and our website (zkoph.com). The interim report of our Company for the six months ended June 30, 2025 containing all the information in accordance with the requirements under the Listing Rules, will be despatched to the Shareholders (if so requested by Shareholders) and published on the respective websites of the Stock Exchange and our Company in due course.

APPRECIATION

We wish to express our sincere gratitude to our Shareholders and business partners for their continued support, and to our employees for their dedication and hard work.

DEFINITIONS

"ANDA"	abbreviated new drug application, an application for a generic drug to an approved drug in China
"Audit Committee"	the audit committee of the Board
"BLA"	biologics license application, an application submitted to the FDA to approve a biologic product for sale in the United States
"Board"	the board of directors of our Company
"CDE"	the Center for Drug Evaluation of NMPA (國家藥品監督管理局藥品審評中心), a division of the NMPA mainly responsible for review and approval of IND and NDA
"CED"	corneal epithelial defect, the partial or complete loss of the epithelial cells in the cornea
"CEO"	the chief executive officer of our Company
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"Chairman"	chairman of the Board
"China" or "the PRC"	the People's Republic of China excluding, for the purpose of this interim results announcement and for geographical reference only and except where the context requires otherwise, Hong Kong, Macau Special Administrative Region and Taiwan

"Company", "our Company", "we", "us", "Zhaoke" or "Zhaoke Ophthalmology"	Zhaoke Ophthalmology Limited
"conjunctivitis"	a disease characterized by the inflammation of the conjunctiva
"Core Product(s)"	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this interim results announcement, our Core Products refer to CsA ophthalmic gel and ZKY001
"corneal ulcers"	open sores or wounds that form on the cornea
"CsA"	a selective immuno-suppressant that inhibits calcineurin, an activator of T cells
"DED"	dry eye disease, a common condition that occurs when tears are unable to provide adequate lubrication for eyes
"Director(s)"	the director(s) of our Company, including all executive directors, non-executive directors and independent non-executive directors
"DME"	diabetic macular edema, a complication of diabetes that causes damage to the macula
"EMA"	European Medicines Agency
"EU"	the European Union
"FDA"	the United States Food and Drug Administration
"glaucoma"	a group of eye diseases that are usually characterized by progressive structural and functional changes of the optic nerve
"Global Offering"	the offer for subscription of the shares as described in the Prospectus
"Greater China"	the PRC, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Group", "our Group", "the Group" or "we"	our Company and its subsidiaries

"HKFRS"	Hong Kong Financial Reporting Standards
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars" or "HK dollars" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"IND"	investigational new drug, the application for which is the first step in the drug review process by regulatory authorities to decide whether to permit clinical trials. Also known as clinical trial application, or CTA, in China
"KOLs"	key opinion leaders, who are professionals that influence their peers' medical practice, including but not limited to prescribing behavior
"Listing"	the listing of our Shares on the Main Board of the Stock Exchange
"Listing Date"	April 29, 2021, being the date on which dealings in our Shares first commence on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with GEM of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"NDA"	new drug application, an application through which the drug sponsor formally proposes that the relevant regulatory authority approve a new drug for sales and marketing
"NMPA"	National Medical Products Administration
"ocular hypertension"	an eye pressure of greater than 21 mm Hg
"ODD"	Orphan Drug Designation
"PGA"	prostaglandin analog

"Prospectus"	the prospectus issued by our Company dated April 16, 2021
"pterygium"	a growth in the cornea or the conjunctiva
"RB"	Retinoblastoma is a rare type of eye cancer that originates in the retina, the light-sensitive tissue at the back of the eye. It primarily affects young children, typically diagnosed before the age of 5
"Reporting Period"	the six months ended June 30, 2025
"RMB"	Renminbi, the lawful currency of the PRC
"R&D"	research and development
"Share(s)"	ordinary shares in the share capital of our Company of US$0.00000025 each
"Shareholder(s)"	holder(s) of Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
"Tenpoint"	Tenpoint Therapeutics Limited (formed through the merger of Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc.), a global clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, is one of our business partners
"TOT BIOPHARM"	TOT BIOPHARM International Company Limited (東曜藥業股份有限公司), a company engaged in research and development, manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization business and license-out of self-developed biological drugs in the PRC, whose shares are listed on the Stock Exchange (stock code: 1875), is one of our business partners
"TPRK"	transepithelial photorefractive keratectomy, a surgical treatment for myopia
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"US$" or "USD"	United States dollars, the lawful currency of the United States

"VEGF"	vascular endothelial growth factor, a signal protein produced by cells that stimulates the formation of blood vessels
"Visus"	Visus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing ophthalmic therapies, which merged with Tenpoint in December 2024 and now operates under the Tenpoint name
"Vyluma"	Vyluma Inc., a biopharmaceutical company specializing in the development and commercialization of ophthalmic treatments, particularly eye drops, is one of our business partners
"wAMD"	wet age-related macular degeneration

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman and executive Director

Hong Kong, August 28, 2025

As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors, Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors, and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.